AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19559158 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening guidelines for osteoporosis in IBD; specific guidelines not detailed.
Number of subjects: 0
Study 17442410 — intervention group
Group type: EXPERIMENTAL
Intervention: K70E mutation
Number of subjects: 10
Study 17442410 — intervention group
Group type: EXPERIMENTAL
Intervention: K65R+K70E mutation
Number of subjects: 10
Study 17442410 — intervention group
Group type: EXPERIMENTAL
Intervention: K65R+K70E+M184V mutations
Number of subjects: 10
Study 17442410 — intervention group
Group type: COMPARATOR
Intervention: K65R+K70E
Number of subjects: 10
Study 17442410 — intervention group
Group type: EXPERIMENTAL
Intervention: K70E
Number of subjects: 10
Study 17442410 — intervention group
Group type: EXPERIMENTAL
Intervention: Double mutant K65R+K70E
Number of subjects: 10
Study 15447896 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscuit meal (17 g SAG/100 g)
Number of subjects: 9
Study 15447896 — intervention group
Group type: COMPARATOR
Intervention: Flakes meal (2 g SAG/100 g)
Number of subjects: 9
Study 12181217 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I‐MIBG study
Number of subjects: 22
Study 12181217 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium201 myocardial perfusion study
Number of subjects: 22
Study 9647493 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5‐10 mg/day)
Number of subjects: 28
Study 9647493 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (40‐120 mg/day)
Number of subjects: 28
Study 8004883 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg cinnarizine
Number of subjects: 108
Study 8004883 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg cinnarizine
Number of subjects: 108
Study 8004883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 2547664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy prior to elective surgery
Number of subjects: 8
Study 2547664 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy (comparison group)
Number of subjects: 8
Study 793113 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine and anti-thymocyte serum (ATS) regimen
Number of subjects: 0
Study 793113 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine-ATG-CY
Number of subjects: 0
Study 793113 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CY) alone
Number of subjects: 0
Study 793113 — intervention group
Group type: COMPARATOR
Intervention: Random donor blood products
Number of subjects: 0
Study 793113 — intervention group
Group type: COMPARATOR
Intervention: Donor or family member transfusions
Number of subjects: 0
Study 793113 — intervention group
Group type: EXPERIMENTAL
Intervention: Second marrow grafts
Number of subjects: 0
Study 793113 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro test for graft rejection prediction
Number of subjects: 0
Study 31447217 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IAS)
Number of subjects: 0
Study 31447217 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PLEX)
Number of subjects: 0
Study 28816165 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton beam therapy
Number of subjects: 201
Study 28816165 — intervention group
Group type: COMPARATOR
Intervention: Intensity modulated radiation therapy (IMRT)
Number of subjects: 201
Study 28816165 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 201
Study 28816165 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior cardiac disease
Number of subjects: 201
Study 28816165 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart volume receiving ≥35 Gy (HV35) >10%
Number of subjects: 201
Study 26270134 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) meal
Number of subjects: 7
Study 26270134 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) meal
Number of subjects: 7
Study 23125444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26-EnvA vaccine (10(9) vp, 10(10) vp, 10(11) vp)
Number of subjects: 60
Study 23125444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26-EnvA vaccine (10(11) vp)
Number of subjects: 60
Study 23125444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26-EnvA vaccine (10(9), 10(10), 10(11) vp 3-dose and 10(10) and 5 × 10(10) vp 2-dose groups
Number of subjects: 60
Study 23125444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21526462 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based case management by health care assistants
Number of subjects: 8
Study 19250788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance liquid chromatographic method for quantification of rimonabant in human plasma
Number of subjects: 0
Study 16627377 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical) 120 mg 3 times daily
Number of subjects: 3305
Study 16627377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3305
Study 16627377 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (Xenical)
Number of subjects: 3305
Study 15545095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540-nm Er:glass laser treatment (5 treatments at 6-week intervals)
Number of subjects: 11
Study 15545095 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatments (2 additional treatments at 14 and 20 months)
Number of subjects: 11
Study 15545095 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-retreated patients)
Number of subjects: 11
Study 10770196 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (fenfluramine, 60 mg/day) with energy restriction (−700 Cal/day)
Number of subjects: 40
Study 9340029 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural patient-controlled analgesia (PCEA) with bupivacaine 0.25% + sufentanil 2 micrograms/ml (bolus 0.05 ml/kg, lockout 10 min)
Number of subjects: 62
Study 9340029 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with morphine (bolus 2 mg, lockout 10 min)
Number of subjects: 62
Study 8332652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal (BF) ECT
Number of subjects: 59
Study 8332652 — intervention group
Group type: COMPARATOR
Intervention: Bitemporal (BT) ECT
Number of subjects: 59
Study 8332652 — intervention group
Group type: COMPARATOR
Intervention: Right Unilateral (RU) ECT
Number of subjects: 59
Study 3979482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (2 mg)
Number of subjects: 10
Study 3979482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30045066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine 1.0-2.0 mg/day
Number of subjects: 231
Study 30045066 — intervention group
Group type: COMPARATOR
Intervention: Cariprazine 0.1-0.3 mg/day
Number of subjects: 231
Study 30045066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 24804780 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence group
Number of subjects: 48
Study 24804780 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence group with family history of alcohol dependence
Number of subjects: 48
Study 24804780 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence group with more frequent drinking
Number of subjects: 48
Study 24804780 — intervention group
Group type: COMPARATOR
Intervention: Psychiatrically healthy adults
Number of subjects: 48
Study 20694822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-radiotherapy fatigue education and support (RFES)
Number of subjects: 110
Study 20694822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-RFES only
Number of subjects: 110
Study 20694822 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-RFES only
Number of subjects: 110
Study 20694822 — intervention group
Group type: COMPARATOR
Intervention: No RFES (standard care)
Number of subjects: 110
Study 16149361 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (CR oxycodone)
Number of subjects: 171
Study 16149361 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 171
Study 12399282 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (thiamine, riboflavin, niacin, folic acid, vitamins B‐6, B‐12, C, and E)
Number of subjects: 1075
Study 12399282 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins including vitamin A
Number of subjects: 1075
Study 12399282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study 9799882 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol 50 mg per day
Number of subjects: 28934
Study 9799882 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene 20 mg per day
Number of subjects: 28934
Study 9799882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both alpha tocopherol and beta carotene
Number of subjects: 28934
Study 9799882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28934
Study 7893315 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale
Number of subjects: 4
Study 7893315 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical Scale
Number of subjects: 4
Study 2777011 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine bicycle exercise
Number of subjects: 50
Study 2777011 — intervention group
Group type: COMPARATOR
Intervention: Upright bicycle exercise
Number of subjects: 50
Study 2777011 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 50
Study 2777011 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of myocardial perfusion using thallium-201 radionuclide ventriculography
Number of subjects: 50
Study 383099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate treatment
Number of subjects: 0
Study 383099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29524793 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional non‐monetary gifts
Number of subjects: 0
Study 29524793 — intervention group
Group type: COMPARATOR
Intervention: Conditional gift based on performance target
Number of subjects: 0
Study 24612734 — intervention group
Group type: EXPERIMENTAL
Intervention: Axaven(®) once a day for 8 months as adjunctive treatment with standard treatment (compression therapy and surgical correction of superficial venous incompetence)
Number of subjects: 83
Study 24612734 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment according to clinical conditions (control group)
Number of subjects: 83
Study 25587162 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal liquid bolus (ELB) albuterol
Number of subjects: 14
Study 25587162 — intervention group
Group type: COMPARATOR
Intervention: Metered-dose inhaler (MDI) albuterol
Number of subjects: 14
Study 23669879 — intervention group
Group type: EXPERIMENTAL
Intervention: CAFF 3mg
Number of subjects: 13
Study 23669879 — intervention group
Group type: EXPERIMENTAL
Intervention: CAFF 6mg
Number of subjects: 13
Study 23669879 — intervention group
Group type: EXPERIMENTAL
Intervention: CAFF 9mg
Number of subjects: 13
Study 23669879 — intervention group
Group type: COMPARATOR
Intervention: PLAC
Number of subjects: 13
Study 19830449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched information
Number of subjects: 1076
Study 19830449 — intervention group
Group type: COMPARATOR
Intervention: Stage-mismatched information
Number of subjects: 1076
Study 19830449 — intervention group
Group type: COMPARATOR
Intervention: General information
Number of subjects: 1076
Study 19830449 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Number of subjects: 1076
Study 19830449 — intervention group
Group type: COMPARATOR
Intervention: Standardized feedback
Number of subjects: 1076
Study 18718737 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (STND)
Number of subjects: 48
Study 18718737 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly digested carbohydrate formula (SDC)
Number of subjects: 48
Study 18718737 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific formula (DSF)
Number of subjects: 48
Study 16384948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 16 mg twice daily for 28 days
Number of subjects: 29
Study 16384948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) (8 mg twice a day, 16 mg per day, or 16 mg twice a day)
Number of subjects: 29
Study 16384948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16384948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX)
Number of subjects: 29
Study 14598034 — intervention group
Group type: EXPERIMENTAL
Intervention: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to students instructed to feign conditions
Number of subjects: 266
Study 14598034 — intervention group
Group type: COMPARATOR
Intervention: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to students responding honestly
Number of subjects: 266
Study 14598034 — intervention group
Group type: EXPERIMENTAL
Intervention: German version of the Structured Inventory of Malingered Symptomatology (SIMS) administered to sexually delinquent patients with antisocial personality disorders
Number of subjects: 266
Study 10965864 — intervention group
Group type: EXPERIMENTAL
Intervention: Video framing the procedure as 99% safe
Number of subjects: 116
Study 10965864 — intervention group
Group type: COMPARATOR
Intervention: Video framing the likelihood of complication as 1 in 100
Number of subjects: 116
Study 10965864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both videos
Number of subjects: 116
Study 8629845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (FK 506) at an initial dose of 0.05 mg/kg per day, increased to 0.10 and 0.15 mg/kg per day if necessary
Number of subjects: 50
Study 8629845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8629845 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (FK 506)
Number of subjects: 50
Study 1475268 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg flupirtine
Number of subjects: 26
Study 1475268 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg flupirtine
Number of subjects: 26
Study 1475268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6427144 — intervention group
Group type: EXPERIMENTAL
Intervention: Added dead space (DS) of 0.25 liter if FEV1 < 0.8, and 0.50 liter if FEV1 > 0.8
Number of subjects: 22
Study 6427144 — intervention group
Group type: COMPARATOR
Intervention: Baseline exercise (BL)
Number of subjects: 22
Study 6427144 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects (9 subjects)
Number of subjects: 22
Study 30328094 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-supervised (intervention)
Number of subjects: 20
Study 30328094 — intervention group
Group type: COMPARATOR
Intervention: Non-supervised (control)
Number of subjects: 20
Study 29648647 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking ≥10 min at a time
Number of subjects: 1214
Study 29648647 — intervention group
Group type: EXPERIMENTAL
Intervention: >4 hours/week of vigorous activity
Number of subjects: 1214
Study 29648647 — intervention group
Group type: COMPARATOR
Intervention: Moderate activity, sitting, and IPAQ categories
Number of subjects: 1214
Study 27277940 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 17
Study 24659064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 22465404 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sun style tai chi exercise
Number of subjects: 503
Study 22465404 — intervention group
Group type: COMPARATOR
Intervention: Seated flexibility exercise
Number of subjects: 503
Study 20538704 — intervention group
Group type: COMPARATOR
Intervention: Disease-modifying treatments (DMTs)
Number of subjects: 100
Study 20538704 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatments (STs)
Number of subjects: 100
Study 18923170 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent type 1 oral poliovirus vaccine
Number of subjects: 530
Study 18923170 — intervention group
Group type: COMPARATOR
Intervention: Trivalent oral poliovirus vaccine
Number of subjects: 530
Study 15892276 — intervention group
Group type: EXPERIMENTAL
Intervention: Erigeron injection (EI) 40 ml/d for 15 days
Number of subjects: 68
Study 15892276 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 68
Study 11936731 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplements for 6 weeks
Number of subjects: 20
Study 11936731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplements)
Number of subjects: 20
Study 9894936 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat shock‐inactivated herpes simplex virus type 1 (10 patients)
Number of subjects: 20
Study 9894936 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study 9894936 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between vaccine and control groups
Number of subjects: 20
Study 7737395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic kinesthetic coordinate system (shoulder angles relative to trunk)
Number of subjects: 7
Study 7737395 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic kinesthetic coordinate system (arm angles relative to earth)
Number of subjects: 7
Study 7737395 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic kinesthetic coordinate system (yaw angles)
Number of subjects: 7
Study 7737395 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevation angles
Number of subjects: 7
Study 2076677 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg chloroquine base weekly for six months
Number of subjects: 17
Study 2076677 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention phase (after chloroquine withdrawal)
Number of subjects: 17
Study 2076677 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months after initiation of chloroquine prophylaxis
Number of subjects: 17
Study 2076677 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of chemoprophylaxis
Number of subjects: 17
Study 7191229 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate, 0.0045 mg/kg IV
Number of subjects: 60
Study 7191229 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate, 0.008 mg/kg IV
Number of subjects: 60
Study 7191229 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, 0.009 mg/kg IV
Number of subjects: 60
Study 31118090 — intervention group
Group type: EXPERIMENTAL
Intervention: MiQuit programme of tailored, interactive text message, and self‐help cessation support for 12 weeks
Number of subjects: 692
Study 31118090 — intervention group
Group type: COMPARATOR
Intervention: Standard NHS smoking cessation support and a leaflet on stopping smoking during pregnancy
Number of subjects: 692
Study 26241157 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget deep brain stimulation (DBS) involving GPi and Vim/Vop
Number of subjects: 1
Study 26241157 — intervention group
Group type: COMPARATOR
Intervention: Single-target deep brain stimulation (DBS)
Number of subjects: 1
Study 23898610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 69
Study 23898610 — intervention group
Group type: COMPARATOR
Intervention: Conventional Radiotherapy
Number of subjects: 69
Study 21849626 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-02413873
Number of subjects: 0
Study 21849626 — intervention group
Group type: COMPARATOR
Intervention: RU-486 (mifepristone)
Number of subjects: 0
Study 19142668 — intervention group
Group type: EXPERIMENTAL
Intervention: HA+FU infusion group
Number of subjects: 16
Study 16905785 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding plus infant zidovudine for 6 months
Number of subjects: 1179
Study 16905785 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding plus infant zidovudine for 1 month
Number of subjects: 1179
Study 15262838 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide with tenecteplase
Number of subjects: 70
Study 11320642 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CRE)
Number of subjects: 16
Study 11320642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 16
Study 9734727 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (high dose: 45 mg x kg body wt(-1) x d(-1))
Number of subjects: 48
Study 9734727 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (low dose: 15 mg x kg body wt(-1) x d(-1))
Number of subjects: 48
Study 9734727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9734727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 48
Study 7999480 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical analgesia
Number of subjects: 45
Study 7999480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal nerve block (midline approach)
Number of subjects: 45
Study 7999480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal nerve block (lateral approach)
Number of subjects: 45
Study 7999480 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 3402466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine hydrochloride
Number of subjects: 12
Study 3402466 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 12
Study 3402466 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 12
Study 31399381 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised mechanical ventilation (based on lung morphology); tidal volume of 8 mL/kg for focal ARDS, 6 mL/kg for non-focal ARDS, low PEEP, recruitment manoeuvres, and prone position.
Number of subjects: 420
Study 31399381 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard care; tidal volume of 6 mL/kg, low PEEP, and encouraged early prone position.
Number of subjects: 420
Study 30095773 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized oxycodone prescription (predicted based on each patient's inpatient opioid use)
Number of subjects: 172
Study 30095773 — intervention group
Group type: COMPARATOR
Intervention: Standard oxycodone prescription (30 tablets of 5 mg oxycodone)
Number of subjects: 172